GLG News by Psychiatrists

This large study shows that PD patients' severity of motor dysfunction is better on rasagiline than on placebo.

More psychiatrists are doing less exclusively psychotherapy in their practices than in past years. The implication is that there is a relatively higher percentage of psychiatrists who will need to know about the latest development of psychopharmacology . Whereas in the past psychiatrists who were psychoanalysts...

All is not as it seems when reported in the press, especially the non-scientific press.

-Pharmacogenetic tests have not made it into the treatment or assessment process for most physicians. -Until the cost for these tests become negligible -- or, included in the cost of a particular antidepressant -- psychopharmacogenetic testing will not make it into the mainstream. 

“Personalized medical diagnositics” looks to be evolving as a high impact area in neuropsychiatric drug development.  Such ‘genetic biomarker’ platforms, based on either pharmacogenetic profiles coming from DNA blueprints or gene products from a simple blood draw, aim to identify patients who are...

The article is indicating ethical measures from the FDA relating to the risk of developing cardiovascular disease from using type 2 diabetes drug. An interesting idea for medical intervention in which decision making is underway to assess the efficacy of clinical trials...

‘One drug, many uses’ can make lots of sense clinically and commercially.   Seeking additional FDA indications for a specific drug has obvious business benefits:  greater revenue stream, improved branding, potentially longer market exclusivity, greater franchising potential of the drug...

Lundbeck has now disclosed the mechanism of action of its “mixed serotonin modulator and stimulator,” albeit buried in a first quarter report.   Data on LuAA21004, Lundbeck’s lead antidepressant jointly in development with Takeda, was released at the Scandinavian College of Neuro-Psychopharmacology...

We need to look to the cause of why we prescribe antipsychotics to patients with dementia.  We have very few tools to use and sometimes these drugs are a necessity.

This news has limited implications for drug development due to the mystery surrounding the causes of Alzheimer's disease. The research reported in this news article is mainly examining the potential primary role of beta-amyloid plaque to cause the onset of Alzheimer's disease. The research is useful...